Table 1 Comparisons of clinicopathologic characteristics of each sub-group categorized by the modes of supplementary androgen deprivation therapy during post-prostatectomy radiotherapy
All patients (n = 227) | Patients with post-radiotherapy BCR (n = 81) | |||||
|---|---|---|---|---|---|---|
No concomitant ADT | Concurrent ADT | p-valuea | No salvage ADT | Salvage ADT | p-valuea | |
Number of patients | 132 | 95 | – | 31 | 50 | – |
Patients characteristics | ||||||
Age (years) | 64.0 (59.3–68.0) | 64.0 (59.0–70.0) | 0.500 | 65.0 (61.0–70.0) | 61.0 (58.0–65.0) | 0.012 |
Pre-operative PSA (ng/mL) | 12.60 (7.00–22.90) | 9.90 (6.90–18.90) | 0.690 | 16.33 (6.40–28.00) | 11.00 (6.55–25.20) | 0.711 |
Pathology-related factors | ||||||
Gleason score | 7 (7–9) | 7 (7–9) | 0.385 | 8 (7–9) | 7 (7–9) | 0.411 |
Pathologic T stage ≥3a | 89 (67.4%) | 56 (58.9%) | 0.190 | 19 (61.3%) | 36 (72.0%) | 0.316 |
Pathologic N stage ≥1 | 4 (3.0%) | 12 (12.6%) | 0.005 | 2 (6.5%) | 1 (2.0%) | 0.302 |
Tumor volume (%) | 10.0 (1.0–20.0) | 9.0 (1.0–17.0) | 0.504 | 9.0 (1.0–20.0) | 2.0 (1.0–16.0) | 0.110 |
Positive surgical margin | 81 (61.4%) | 59 (62.1%) | 0.910 | 19 (61.3%) | 27 (54.0%) | 0.520 |
ADT-related factors | ||||||
Concomitant ADT duration (months) | – | 17.0 (12.0–21.0) | – | – | – | – |
Salvage ADT duration (months) | – | – | – | – | 16.0 (3.8–51.3) | – |
Initial regimen | ||||||
Complete androgen blockage | – | 43 (45.3%) | – | – | 8 (16.0%) | |
LHRH agonist | – | 31 (32.6%) | – | 32 (64.0%) | ||
Antiandrogen | – | 21 (22.1%) | – | 10 (20.0%) | ||
Radiotherapy-related factors | – | |||||
Pre-radiotherapy PSA (ng/mL) | 0.39 (0.25–0.60) | 0.72 (0.50–1.10) | < 0.001 | 0.42 (0.32–0.75) | 0.71 (0.39–1.63) | 0.007 |
Radiotherapy dose (Gy) | 66.0 (66.0–70.0) | 66.0 (66.0–66.0) | 0.117 | 66.0 (66.0–70.0) | 66.0 (66.0–70.0) | 0.607 |